Cargando…

The clinical relevance of autoantibodies in scleroderma

Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Khanh T, Reveille, John D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165038/
https://www.ncbi.nlm.nih.gov/pubmed/12718748
_version_ 1782120823194124288
author Ho, Khanh T
Reveille, John D
author_facet Ho, Khanh T
Reveille, John D
author_sort Ho, Khanh T
collection PubMed
description Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently and are also predictive of diffuse skin involvement and systemic disease. Anti-Th/To and PM-Scl, in contrast, are associated with limited skin disease, but anti-Th/To might be a marker for the development of pulmonary hypertension. Other autoantibodies against extractable nuclear antigens have less specificity for SSc, including anti-Ro, which is a risk factor for sicca symptoms in patients with SSc, and anti-U1-ribonucleoprotein, which in high titer is seen in patients with SSc/systemic lupus erythematosus/polymyositis overlap syndromes. Limited reports of other autoantibodies (anti-Ku, antiphospholipid) have not established them as being clinically useful in following patients with SSc.
format Text
id pubmed-165038
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1650382003-07-12 The clinical relevance of autoantibodies in scleroderma Ho, Khanh T Reveille, John D Arthritis Res Ther Review Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently and are also predictive of diffuse skin involvement and systemic disease. Anti-Th/To and PM-Scl, in contrast, are associated with limited skin disease, but anti-Th/To might be a marker for the development of pulmonary hypertension. Other autoantibodies against extractable nuclear antigens have less specificity for SSc, including anti-Ro, which is a risk factor for sicca symptoms in patients with SSc, and anti-U1-ribonucleoprotein, which in high titer is seen in patients with SSc/systemic lupus erythematosus/polymyositis overlap syndromes. Limited reports of other autoantibodies (anti-Ku, antiphospholipid) have not established them as being clinically useful in following patients with SSc. BioMed Central 2003 2003-02-12 /pmc/articles/PMC165038/ /pubmed/12718748 Text en Copyright © 2003 BioMed Central Ltd
spellingShingle Review
Ho, Khanh T
Reveille, John D
The clinical relevance of autoantibodies in scleroderma
title The clinical relevance of autoantibodies in scleroderma
title_full The clinical relevance of autoantibodies in scleroderma
title_fullStr The clinical relevance of autoantibodies in scleroderma
title_full_unstemmed The clinical relevance of autoantibodies in scleroderma
title_short The clinical relevance of autoantibodies in scleroderma
title_sort clinical relevance of autoantibodies in scleroderma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC165038/
https://www.ncbi.nlm.nih.gov/pubmed/12718748
work_keys_str_mv AT hokhanht theclinicalrelevanceofautoantibodiesinscleroderma
AT reveillejohnd theclinicalrelevanceofautoantibodiesinscleroderma
AT hokhanht clinicalrelevanceofautoantibodiesinscleroderma
AT reveillejohnd clinicalrelevanceofautoantibodiesinscleroderma